Floatz logo

11 assets in Oral Cavity Squamous Cell Carcinoma

Therapeutic assets addressing Oral Cavity Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Oral Cavity Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2B (57)
Abiraterone
Oral Cavity Squamous Cell Carcinoma
MacroGenicsP2CCC (53)
Cabozantinib
Oral Cavity Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Enzalutamide
Oral Cavity Squamous Cell Carcinoma
MacroGenicsP2CCC (53)
Nivolumab
Oral Cavity Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Oral Cavity Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2CCC (48)
Docetaxel
Oral Cavity Squamous Cell Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Pembrolizumab
Oral Cavity Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2CCC (48)
SX682
Oral Cavity Squamous Cell Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Vobramitamab Duocarmazine
Oral Cavity Squamous Cell Carcinoma
MacroGenicsP2C (36)
CHG0521
Oral Cavity Squamous Cell Carcinoma
Guangzhou University of Traditional Chinese MedicineN/ANR ()